A

ABL Bio Inc
KOSDAQ:298380

Watchlist Manager
ABL Bio Inc
KOSDAQ:298380
Watchlist
Price: 27 150 KRW 2.84% Market Closed
Market Cap: 1.3T KRW
Have any thoughts about
ABL Bio Inc?
Write Note

ABL Bio Inc
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ABL Bio Inc
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
A
ABL Bio Inc
KOSDAQ:298380
Capital Expenditures
-â‚©9.3B
CAGR 3-Years
-82%
CAGR 5-Years
-54%
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Capital Expenditures
-â‚©327.4B
CAGR 3-Years
18%
CAGR 5-Years
-4%
CAGR 10-Years
-11%
SK Bioscience Co Ltd
KRX:302440
Capital Expenditures
-â‚©50.3B
CAGR 3-Years
-70%
CAGR 5-Years
-51%
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
Capital Expenditures
-â‚©29.4B
CAGR 3-Years
19%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Capital Expenditures
-â‚©29.3B
CAGR 3-Years
0%
CAGR 5-Years
-18%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Capital Expenditures
-â‚©32.9B
CAGR 3-Years
-33%
CAGR 5-Years
-47%
CAGR 10-Years
N/A
No Stocks Found

ABL Bio Inc
Glance View

Market Cap
1.3T KRW
Industry
Biotechnology

ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.

Intrinsic Value
8 401.38 KRW
Overvaluation 69%
Intrinsic Value
Price
A

See Also

What is ABL Bio Inc's Capital Expenditures?
Capital Expenditures
-9.3B KRW

Based on the financial report for Jun 30, 2024, ABL Bio Inc's Capital Expenditures amounts to -9.3B KRW.

What is ABL Bio Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-54%

Over the last year, the Capital Expenditures growth was -564%. The average annual Capital Expenditures growth rates for ABL Bio Inc have been -82% over the past three years , -54% over the past five years .

Back to Top